This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
Patients who complete the Part 2 Week 28 visit in study KNS-760704-CL201 and patients with ALS who were actively receiving RTPB [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydro-chloride monohydrate] under Research IND #60,948 were eligible to participate in this study. Eligible patients received 1 tablet of KNS-760704 (150 mg) every 12 hours (Q12H) (300 mg total daily dose) for up to 180 weeks.
Inclusion Criteria:
1. Patient has provided signed informed consent for this trial before the commencement of
any study-related procedure
2. Patient is actively participating in Knopp Protocol KNS-760704-CL201 and has completed
the Part 2 Week 28 visit in that study or patient is actively receiving RTPB under
Research IND #60,948
Exclusion Criteria:
1. Patient did not participate in Knopp Protocol KNS-760704-CL201 or patient did not
receive RTPB under Research IND #60,948.
2. Patient discontinued from KNS-760704-CL201 for any reason other than enrollment into
this study (applies to patients enrolled in KNS-760704-CL201 only)
3. Patient was not taking RTPB under Research IND #60,948 prior to April 30, 2009
(applies to patients enrolled under Research IND #60,948 only)